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Background: Hepatitis E Virus (HEV) infection has a poor prognosis among pregnant women from high endemic
countries. HEV-prevalence and incidence among pregnant women is unknown in high-income countries such as
France. This prospective study was conducted to assess HEV infection in this setting.
Findings: An overall HEV prevalence of 7.74% was observed among 315 pregnant women. Seroprevalence was
higher in south than in north of France (29.3% vs. 3.6%, p < 0.0001), and women with detectable IgG were older.
No IgG seroconversion or IgM detection were observed during pregnancy.
Conclusions: Data suggest that HEV infection is a rare occurrence during pregnancy even in regions of western
countries with high seroprevalence rates.
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Hepatitis E virus (HEV) infection is associated with two
distinct patterns of disease [1]. In low income countries
with poor sanitation and hygiene, HEV is a common
cause of acute hepatitis, and is responsible for water-
borne outbreaks and sporadic cases due to genotype 1
or 2 that exclusively infect humans. Disease has a high
attack rate in young adults and is particularly severe
among pregnant women where the mortality secondary
to symptomatic infection was estimated tenfold higher
than in men or non-pregnant women [2]. In high in-
come countries, HEV is responsible for sporadic cases
due to genotypes 3 and 4 that also infect other animals,
and zoonotic and food-borne transmission is suggested
[1]. In these countries, the clinical presentation differs
from disease in high endemic areas, including older age,
more marked male predominance, higher frequency of
underlying liver disease, and a lack of severe disease
among pregnant women. Indeed, only few cases of hepa-
titis E during pregnancy have been reported [3,4] and* Correspondence: anne-marie.roque@pbr.aphp.fr
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unless otherwise stated.none with severe hepatitis. The role of nutritional, im-
munological, and genetic factors has been suggested in
the pathophysiology of fulminant HEV during pregnancy
in developing countries but the distinct clinical pattern be-
tween low and high income countries is still not under-
stood. It may reflect differences in disease biology between
different HEV genotypes but also a reduced exposure to
the virus because endemicity is low and/or undiagnosed
asymptomatic or pauci-symptomatic infections in high in-
come countries.Methods
This prospective study was conducted to assess HEV
prevalence and incidence among pregnant women from
two hospitals in north (Meaux) and south-east (Hyères) of
France. The protocol was approved by the ethical commit-
tee of Le Kremlin Bicêtre (France) and written consent was
obtained from pregnant women. Blood samples were taken
at the beginning of pregnancy and in postpartum. HEV ser-
ology (IgG and IgM) was performed with the Wantai im-
munoassay (Beijing, China). A questionnaire listing HEV
risk factors was given at the time of sampling.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Renou et al. Virology Journal 2014, 11:68 Page 2 of 3
http://www.virologyj.com/content/11/1/68Results
Serological data were available for 315 women at the
beginning of pregnancy, 255 in north and 60 in south-
east France. The overall HEV prevalence was 7.74% (CI
4.7%-10.8%). Seroprevalence was higher in south than in
north: 29.3% (CI 15.3%-43.2%) vs. 3.6% (CI 1.3%-5.9%).
Women with detectable IgG by the Wantai assay were
older: 32.5+/-5 vs. 29.4+/-5 years (p = 0.012). No IgM
positivity was detected in early pregnancy. Postpartum
serology was available for 140 women (44.4%), in an aver-
age of 6.4+/-1.7 months’ interval after initial sampling. No
IgG seroconversion or IgM detection were observed in
this second sampling.
Completed questionnaires were available at the beginning
of the pregnancy in 188 cases (59.6%). No difference was
observed between women with and without IgG regarding
trips abroad (p = 0.5), urban vs. rural residence (p = 0.41),
seafood consumption (p = 0.38), pet ownership (p = 0.18) or
pork liver consumption (p = 0.14). None of the HEV IgG-
positive women reported a history of liver disease.
Discussion and conclusion
Though studies on HEV IgG seroprevalence among
blood donors [5-7] or epidemiologically exposed subjects
[8] are available from France, there is a lack of data with
respect to pregnant women. Indeed, pregnant women
are usually followed as outpatients by gynecologists and
HEV is still considered as a rare and exotic disease this
setting. Analysis of reported seroprevalence rates has
also to take into account the use of assays with different
sensitivities and the geographical origin of recruited sub-
jects. Indeed, by using more sensitive assays, recent HEV
IgG seroprevalence studies conducted in France have
produced much higher results than earlier studies [7].
Significant epidemiological differences also exist within
the same country: previous studies have reported sero-
prevalence rates among blood donors five-fold higher in
south-west (16.6%) [5] than in north of France (3.2%),
though using the same assay [6]. This finding was con-
firmed by a higher frequency of clinically apparent HEV
infections in the south of France [9]. The present study
confirms this north-south gradient in a population of
pregnant women, with much higher rates in south-east
France. Reasons for this striking difference are still
unknown, and the present study failed to identify life
style factors that may explain this gradient. Seropreva-
lence rates reported here may appear lower than those
recently reported in other French populations. However,
we found HEV IgG positivity associated with age and
it is noteworthy from previous studies that the prob-
ability of being exposed to HEV increases with age [6,7].
Our finding of a 29.3% of HEV seroprevalence in south-
east France with the Wantai assay is in line with the
results from Mansuy et al. who reported a rate over40% in blood donors from south-west France aged 28
to 37 years [7].
The high HEV seroprevalence, particularly in south of
France, at the onset of the pregnancy in women who re-
port no history of liver disease confirms that most infec-
tions are subclinical or unrecognized. Concerning the
incidence of HEV infection among pregnant women in
western countries, a rate of 0.67% of IgM anti-HEV was
shown in a Spanish cohort during the first trimester of
pregnancy [10] but no clinical symptoms and normal
aminotransferases levels were reported, suggesting either
false-positive results or silent forms of infection. In the
present study, no markers of acute infection and no
seroconversion were observed during pregnancy. This
absence of infection even in an area with a significant
circulation of the virus, like south-east of France may be
due to the relatively short time span between samplings
(6 months) but also to dietary measures taken by preg-
nant women to prevent infectious diseases such as toxo-
plasmosis that could have protect them also from HEV.
However, the number of questionnaires returned at the
end of pregnancy was too small to assess this hypothesis.
Finally, this prospective study assessed for the first
time the HEV prevalence and incidence during preg-
nancy in France and suggests that this infection is a rare
occurrence during pregnancy, even in high endemic re-
gions of western countries.
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